Citation

Nittner-Marszalska M, Liebhart J, Dor-Wojnarowska A. Int. J. Immunopathol. Pharmacol. 2015; 28(2): 187-193.

Affiliation

Department of Internal Diseases, Geriatrics and Allergology Medical University, Wroclaw, Poland dor_anna@yahoo.co.uk.

Copyright

(Copyright © 2015, Biolife)

DOI

10.1177/0394632015586143

PMID

26078379

Abstract

Experimental studies, epidemiological data, and clinical observations suggest that the gender factor is involved in the development and manifestation of IgE-dependent allergic diseases. We intend to answer the question if sex-related factors may play a role in Hymenoptera venom allergy (HVA). In the majority of recent studies the frequency of HVA symptoms with respect to both LL and SYS reactions is similar for men and women, while proven sensitization to insect venom is less frequent in women. Studies assessing clinical reactivity in HVA indicate that male sex and vespid venom allergy are factors increasing the risk of severe allergic reactions. Regarding the risk of adverse events associated with gender in the course of venom immunotherapy (VIT), the results of two large EAACI multicenter studies are discordant. In the first study, women showed increased risk of VIT adverse events. In the latter, systemic allergic side effects were not associated with gender. Despite theoretical premises and certain clinical observations indicating an important role of estrogens in allergic diseases, their influence on stinging insects' venom hypersensitivity is not unequivocal and remains still open. Further studies on the safety of VIT in females seem to be advisable.

Language: en